-
-
Humanized model of the immune system
-
iHuPBMC-T
-
iHuPBMC-NK
-
iHuPBMC-B
-
PBMC-LT
-
CD34+ HSC
-
Winn model
-
iHuPBMC-MHC/KO
-
iHuPBMC-OncVax
-
PBMC mixed inoculation model
more -
-
In vivo tumor experimental platform
-
CDX
-
iHuPDX
-
Non-GLP Toxicology
-
PK/PD
-
Brain in situ model
-
Other in situ models
-
Hematologic tumor model system inoculation
-
Creation of high interstitial tumor models
more -
-
In vitro killing experiment platform
-
Immune co-culture killing model
-
CDC
-
In vitro killing experiment platform
-
IC50
-
PDC High-Throughput In Vitro Pharmacodynamics
-
3D organoids
-
ADCC
-
T cell-mediated killing experiment
more -
-
Mouse-derived immune system model
more -
Tumor vaccine
more -
Cell therapy
more -
In vitro testing platform
more -
Non-GLP Toxicology Platform
more -
Non-tumor model and drug efficacy evaluation platform
-
Systematic Vaccination Model
-
Non-tumor model and drug efficacy evaluation platform
-
Skin injury model
-
Stroke model
-
Liver fibrosis model
-
Diabetes model
-
Gouty Arthritis (GA) Model
-
Pulmonary fibrosis model
-
Systemic lupus erythematosus (SLE) model
-
Inflammatory Bowel Disease (IBD) model
-
Rheumatoid Arthritis (RA) Model
more -
-
-
-
PDX model
-
PDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
CDX model
-
CDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
Homogeneous Model
-
Homogeneous Model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Breast cancer
-
Stomach cancer
-
Liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Pancreatic cancer
-
Kidney cancer
-
Bladder cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer
-
Ovarian cancer
-
Esophageal cancer
-
Skin cancer
-
sarcoma
-
Nervous System Cancer
-
Embryonal carcinoma
-
Lymphoma
-
Leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other
-
Colorectal cancer
more -
-
News Center
——
InnoModels: Characteristics of CD34+ HSC Mouse Model
Author:
InnoModels
Release time:
2024-03-04
With the rapid development of life science, animal models play an increasingly important role in biomedical research. Among them, the CD34+ HSC mouse model launched by InnoModels Biotechnology provides researchers with an efficient and reliable experimental tool by virtue of its unique advantages. In this article, we will introduce the features of the CD34+ HSC model of InnoModels Biotechnology in detail.
Model Overview:
The CD34+ HSC mouse model is an animal model expressing human CD34+ hematopoietic stem cells (Hematopoietic Stem Cells, HSCs) successfully constructed by InnoModels Biotechnology using advanced gene editing technology in mice. This model can mimic part of the function of the human hematopoietic system, which provides powerful support for the study of blood diseases, drug screening and regenerative medicine.
Model features:
1. Highly simulate the human hematopoietic system: the hematopoietic stem cells in the CD34+ HSC mouse model have a high potential for self-renewal and differentiation, and are able to mimic the physiological and pathological processes of the human hematopoietic system, which provides an important basis for the study of the pathogenesis and therapeutic strategies of blood diseases.
2. High stability: CD34+ expression in mouse hematopoietic stem cells achieved by gene editing technology is highly stable, and can maintain stable genetic characteristics in multiple generations of mice, ensuring the reliability and reproducibility of experimental results.
3. Easy to operate: The model mice are relatively simple to feed and manage, and the experiments are easy to operate, which is suitable for various experimental techniques, such as flow cytometry and microscopic observation.
4. Wide application prospects: The CD34+ HSC mouse model has wide application prospects in the fields of blood disease research, drug screening, regenerative medicine and immunology. Through this model, researchers can deeply study the biological characteristics of hematopoietic stem cells and provide new ideas and methods for the treatment of blood diseases.

Application fields:
1. blood disease research: using the CD34+ HSC mouse model, researchers can simulate the pathogenesis of various blood diseases, such as leukemia, anemia, etc., so as to study the pathogenesis of these diseases in depth, and provide strong support for the search of effective treatment methods.
2. Drug Screening: The model can be used as an important tool for drug screening, providing an important reference for drug development by evaluating the efficacy of different drugs in the model mice.
3. Regenerative medicine: CD34+ HSC mouse models provide an important experimental platform for regenerative medicine. Researchers can use these mice models for hematopoietic stem cell transplantation, tissue engineering and other studies, providing new possibilities for future medical treatments.
Summary:
By virtue of its high simulation of the human hematopoietic system, stability, ease of operation, and wide range of application prospects, the InnoModels Biotechnology CD34+ HSC mouse model opens up a new path for biomedical research. With the in-depth study of this model by researchers, it is believed that more breakthroughs will be achieved in the future in the fields of blood disease treatment, drug screening and regenerative medicine.
InnoModels Biotechnology (Beijing) Co., Ltd.
-
TEL: +86 15711355061
-
E-mail: xuyl@imodels.tech
-
Address: Building 14, No. 79 West Shuangying Road, Changping District, Beijing
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.
These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.
These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.
These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.
InnoModels Biotechnology (Beijing) Co., Ltd